Drug company Pfizer has submitted its COVID-19 pill treatment to the U.S. Food and Drug Administration (FDA) for authorization to be used for certain people.
On Tuesday, Pfizer announced that “it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, PAXLOVID™ […] for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death.”
“If authorized or approved, PAXLOVID would be the first oral antiviral of its kind … that could be prescribed as an at-home treatment to high-risk patients at the first sign of infection, potentially helping patients avoid severe illness which can lead to hospitalization and death,” the announcement noted.
The Wall Street Journal reported, “Initial supplies of Pfizer’s pill would be limited. Pfizer projects it will manufacture more than 180,000 courses of treatment this year, and plans to increase production to at least 50 million courses next year.” – READ MORE